Ana Hernández-García
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ana Hernández-García has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Angel Cogolludo
Universidad Complutense de Madrid
7 shared publications - Jorge Rodríguez-Pérez
Universidad Autónoma de Madrid, Spain
4 shared publications - Rosa Andreu-Martínez
Universidad Autónoma de Madrid, Spain
4 shared publications - Bianca Barreira
Universidad Complutense de Madrid
3 shared publications - Daniel Morales-Cano
Centro Nacional de Investigaciones Cardiovasculares Carlos III
3 shared publications - María José Calzada
Department of Medicine, School of Medicine, Universidad Autónoma of Madrid, 28029 Madrid, Spain
3 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1040
Pharmacological activation of sigma-1 receptor by clinically approved drugs enhances KV1.5 channel activity in the pulmonary circulation
- 31 October 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1040
Open AccessPharmacological activation of sigma-1 receptor by clinically approved drugs enhances KV1.5 channel activity in the pulmonary circulation
- Open Access
- 16 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5426
Pulmonary Immune Cell Landscape Altered by Exposure to HIV, Schistosoma and Their Combination
Local immune cell activation and vascular remodelling are characteristic pathogenic features of pulmonary arterial hypertension (PAH). HIV and schistosome infections have been individually associated with PAH. However, whether co-infection with these pathogens has a distinct impact on the development of pulmonary vascular disease remains poorly understood, partly due to the lack of experimental animal models. In a novel non-infectious model of HIV and Schistosoma pulmonary co-exposure based on lung embolisation of S. mansoni eggs in HIV-transgenic (HIV) mice, we previously reported exacerbated endothelial remodelling and dysfunction, along with increased pulmonary arterial pressure; which were associated with a unique profile of pro-inflammatory cytokines in the lung. In the present study, we used flow cytometric analysis of isolated lung leukocytes and immunofluorescence staining to characterise the pulmonary immune cell landscape associated with individual or combined exposure to HIV and schistosome. Compared with mice exposed to HIV (untreated HIV mice) or schistosome (egg-treated wild-type mice), co-exposed (egg-treated HIV mice) animals showed significantly increased numbers of interstitial and alveolar macrophages, patrolling-type monocytes, NKT and γδ T cells, and reduced CD8+ αβ T cells. Other lung immune cells, including inflammatory-type monocytes, eosinophils/neutrophils, dendritic cells, CD4+ αβ T cells, NK cells and B cells were not significantly affected in the co-exposure condition. Taken together, these results show for the first time that combined pulmonary exposure to HIV and Schistosoma, as it may occur in co-infected individuals, alters the local immune cell landscape in a manner distinct from that of individual exposure. Furthermore, these findings may contribute to a better understanding of the complex inflammatory processes involved in the pathogenesis of PAH, thereby supporting the development of therapies targeting pathogenic immune cells in pulmonary vascular disease associated with HIV and Schistosoma co-morbidity.
- 16 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (12) , 5426
Open AccessPulmonary Immune Cell Landscape Altered by Exposure to HIV, Schistosoma and Their Combination
Local immune cell activation and vascular remodelling are characteristic pathogenic features of pulmonary arterial hypertension (PAH). HIV and schistosome infections have been individually associated with PAH. However, whether co-infection with these pathogens has a distinct impact on the development of pulmonary vascular disease remains poorly understood, partly due to the lack of experimental animal models. In a novel non-infectious model of HIV and Schistosoma pulmonary co-exposure based on lung embolisation of S. mansoni eggs in HIV-transgenic (HIV) mice, we previously reported exacerbated endothelial remodelling and dysfunction, along with increased pulmonary arterial pressure; which were associated with a unique profile of pro-inflammatory cytokines in the lung. In the present study, we used flow cytometric analysis of isolated lung leukocytes and immunofluorescence staining to characterise the pulmonary immune cell landscape associated with individual or combined exposure to HIV and schistosome. Compared with mice exposed to HIV (untreated HIV mice) or schistosome (egg-treated wild-type mice), co-exposed (egg-treated HIV mice) animals showed significantly increased numbers of interstitial and alveolar macrophages, patrolling-type monocytes, NKT and γδ T cells, and reduced CD8+ αβ T cells. Other lung immune cells, including inflammatory-type monocytes, eosinophils/neutrophils, dendritic cells, CD4+ αβ T cells, NK cells and B cells were not significantly affected in the co-exposure condition. Taken together, these results show for the first time that combined pulmonary exposure to HIV and Schistosoma, as it may occur in co-infected individuals, alters the local immune cell landscape in a manner distinct from that of individual exposure. Furthermore, these findings may contribute to a better understanding of the complex inflammatory processes involved in the pathogenesis of PAH, thereby supporting the development of therapies targeting pathogenic immune cells in pulmonary vascular disease associated with HIV and Schistosoma co-morbidity.
- Open Access
- 17 February 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 196, 119115
The Sigma-1 receptor agonist PRE084 improves cardiopulmonary function and remodelling in an experimental model of pulmonary arterial hypertension
- 17 February 2026
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 196, 119115
Open AccessThe Sigma-1 receptor agonist PRE084 improves cardiopulmonary function and remodelling in an experimental model of pulmonary arterial hypertension
- Top Cited PapersOpen Access
- 8 July 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (7) , 839
Oxidative Stress and Inflammation in Hypoxemic Respiratory Diseases and Their Comorbidities: Molecular Insights and Diagnostic Advances in Chronic Obstructive Pulmonary Disease and Sleep Apnea
In chronic respiratory diseases (CRDs), oxidative stress and inflammation are closely linked, driving disease onset, progression, and comorbidities. Oxidative stress activates inflammatory pathways, while chronic inflammation promotes further reactive oxygen species (ROS) production, creating a vicious cycle leading to airway remodeling, reduced lung function, and exacerbations. This review highlights the central roles of inflammation and oxidative stress in chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA). In COPD, chronic hypoxemia associates with emphysema, appearing with disease progression. In OSA, beyond systemic consequences, pulmonary inflammation and oxidative stress contribute to lung injury as well. Although COPD and OSA are distinct conditions, some patients present with “overlap syndrome”, a term used in this review to describe the coexistence of both. This combination poses unique diagnostic and therapeutic challenges. We also examine the role of hypoxia and its transcriptional effects via hypoxia-inducible factors (HIFs) in promoting oxidative stress and inflammation. Finally, we explore how artificial intelligence (AI) offers promising tools to improve diagnosis, monitoring, and management of CRDs and may help elucidate mechanistic links between hypoxia, inflammation, and oxidative stress, contributing to more personalized therapeutic strategies.
- 8 July 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (7) , 839
Top Cited PapersOpen AccessOxidative Stress and Inflammation in Hypoxemic Respiratory Diseases and Their Comorbidities: Molecular Insights and Diagnostic Advances in Chronic Obstructive Pulmonary Disease and Sleep Apnea
In chronic respiratory diseases (CRDs), oxidative stress and inflammation are closely linked, driving disease onset, progression, and comorbidities. Oxidative stress activates inflammatory pathways, while chronic inflammation promotes further reactive oxygen species (ROS) production, creating a vicious cycle leading to airway remodeling, reduced lung function, and exacerbations. This review highlights the central roles of inflammation and oxidative stress in chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA). In COPD, chronic hypoxemia associates with emphysema, appearing with disease progression. In OSA, beyond systemic consequences, pulmonary inflammation and oxidative stress contribute to lung injury as well. Although COPD and OSA are distinct conditions, some patients present with “overlap syndrome”, a term used in this review to describe the coexistence of both. This combination poses unique diagnostic and therapeutic challenges. We also examine the role of hypoxia and its transcriptional effects via hypoxia-inducible factors (HIFs) in promoting oxidative stress and inflammation. Finally, we explore how artificial intelligence (AI) offers promising tools to improve diagnosis, monitoring, and management of CRDs and may help elucidate mechanistic links between hypoxia, inflammation, and oxidative stress, contributing to more personalized therapeutic strategies.
- Open Access
- 10 June 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (6) , 703
CSE-Induced ER-Mitochondria Crosstalk Promotes Oxidative Stress and Impairs Bronchial Contractile Response
Chronic obstructive pulmonary disease (COPD), whose main risk factor is cigarette smoking, is among the most prevalent diseases worldwide. Previous studies have shown that cigarette smoke extract (CSE) can directly affect pulmonary artery function independently of hypoxia resulting from the airway obstruction. In addition, CSE also affects bronchial smooth muscle, leading to airway hyper-responsiveness. However, its specific impact on the contractile machinery of this compartment remains unclear. In this study, using in vitro experiments with human bronchial smooth muscle cells (hBSMCs), we found that CSE exposure disrupted calcium homeostasis, increased ROS and lipid peroxidation, and reduced cell antioxidant defenses. Furthermore, CSE exposure altered the cell contractile apparatus by decreasing key cytoskeletal proteins and impairing actin dynamics, potentially contributing to the dysregulated contractile response of cells. Notably, these effects were significantly attenuated by antioxidant drugs such as mitoTEMPO and N-acetylcysteine, as well as by the inhibition of the endoplasmic reticulum (ER) calcium channels with 2-aminoethoxydiphenyl borate (2-APB). More importantly, mitoTEMPO partially restored the contractile response of bronchus upon CSE challenge. Collectively, our findings give evidence that CSE-mediated increase in ROS and intracellular calcium contribute to cytoskeletal disruption and functional impairment in airway smooth muscle. Moreover, these results also point to potential therapeutical approaches for mitigating the harmful effects of cigarette smoke in the lung.
- 10 June 2025
- Published by MDPI AG in Antioxidants
- Vol. 14 (6) , 703
Open AccessCSE-Induced ER-Mitochondria Crosstalk Promotes Oxidative Stress and Impairs Bronchial Contractile Response
Chronic obstructive pulmonary disease (COPD), whose main risk factor is cigarette smoking, is among the most prevalent diseases worldwide. Previous studies have shown that cigarette smoke extract (CSE) can directly affect pulmonary artery function independently of hypoxia resulting from the airway obstruction. In addition, CSE also affects bronchial smooth muscle, leading to airway hyper-responsiveness. However, its specific impact on the contractile machinery of this compartment remains unclear. In this study, using in vitro experiments with human bronchial smooth muscle cells (hBSMCs), we found that CSE exposure disrupted calcium homeostasis, increased ROS and lipid peroxidation, and reduced cell antioxidant defenses. Furthermore, CSE exposure altered the cell contractile apparatus by decreasing key cytoskeletal proteins and impairing actin dynamics, potentially contributing to the dysregulated contractile response of cells. Notably, these effects were significantly attenuated by antioxidant drugs such as mitoTEMPO and N-acetylcysteine, as well as by the inhibition of the endoplasmic reticulum (ER) calcium channels with 2-aminoethoxydiphenyl borate (2-APB). More importantly, mitoTEMPO partially restored the contractile response of bronchus upon CSE challenge. Collectively, our findings give evidence that CSE-mediated increase in ROS and intracellular calcium contribute to cytoskeletal disruption and functional impairment in airway smooth muscle. Moreover, these results also point to potential therapeutical approaches for mitigating the harmful effects of cigarette smoke in the lung.
- Open Access
- 15 May 2025
- Published by MDPI AG in Preprints.org
Cse-Induced Er-Mitochondria Crosstalk Promotes Oxidative Stress and Impairs Bronchial Contractile Response
Chronic obstructive pulmonary disease (COPD), whose main risk factor is cigarette smoking, is among the most prevalent diseases worldwide. Previous studies have shown that cigarette smoke extract (CSE) can directly affect pulmonary artery function independently of hypoxia resulting from the airway obstruction. In addition, CSE also affects bronchial smooth muscle, leading to airway hyper-responsiveness. However, its specific impact on the contractile machinery of this compartment remains unclear. In this study, using in vitro experiments with human bronchial smooth muscle cells (hBSMC) we found that CSE exposure disrupted calcium homeostasis, increased ROS and lipid peroxidation, and reduced cell antioxidant defenses. Furthermore, CSE exposure altered the cell contractile apparatus by decreasing key cytoskeletal proteins and impairing actin dynamics, this potentially contributing to cell dysregulated contractile response. Notably, these effects were significantly attenuated by antioxidant drugs such as mitoTEMPO and N-acetylcysteine, as well as by the inhibition of the RE calcium channels with 2-aminoethoxydiphenyl borate (2-APB). More importantly, mitoTEMPO partially restored the contractile response of bronchus upon CSE challenge. Collectively, our findings give evidence that CSE-mediated increase in ROS and intracellular calcium contribute to cytoskeletal disruption and functional impairment in airway smooth muscle. Moreover, these results also point to potential therapeutical approaches for mitigating the harmful effects of cigarette smoke in the lung.
- 15 May 2025
- Published by MDPI AG in Preprints.org
Open AccessCse-Induced Er-Mitochondria Crosstalk Promotes Oxidative Stress and Impairs Bronchial Contractile Response
Chronic obstructive pulmonary disease (COPD), whose main risk factor is cigarette smoking, is among the most prevalent diseases worldwide. Previous studies have shown that cigarette smoke extract (CSE) can directly affect pulmonary artery function independently of hypoxia resulting from the airway obstruction. In addition, CSE also affects bronchial smooth muscle, leading to airway hyper-responsiveness. However, its specific impact on the contractile machinery of this compartment remains unclear. In this study, using in vitro experiments with human bronchial smooth muscle cells (hBSMC) we found that CSE exposure disrupted calcium homeostasis, increased ROS and lipid peroxidation, and reduced cell antioxidant defenses. Furthermore, CSE exposure altered the cell contractile apparatus by decreasing key cytoskeletal proteins and impairing actin dynamics, this potentially contributing to cell dysregulated contractile response. Notably, these effects were significantly attenuated by antioxidant drugs such as mitoTEMPO and N-acetylcysteine, as well as by the inhibition of the RE calcium channels with 2-aminoethoxydiphenyl borate (2-APB). More importantly, mitoTEMPO partially restored the contractile response of bronchus upon CSE challenge. Collectively, our findings give evidence that CSE-mediated increase in ROS and intracellular calcium contribute to cytoskeletal disruption and functional impairment in airway smooth muscle. Moreover, these results also point to potential therapeutical approaches for mitigating the harmful effects of cigarette smoke in the lung.
- Open Access
- 15 May 2025
- Published by MDPI AG in Preprints.org
Oxidative Stress and Inflammation in COPD and Sleep Apnea and Its Comorbidities. Molecular Insights and Artificial Intelligence Approaches in Diagnosis and Prognosis
In chronic respiratory diseases (CRDs), oxidative stress and inflammation exhibit a strong pathophysiological interplay, playing essential roles in the onset and progression of these conditions and their associated comorbidities. Oxidative stress can activate inflammatory pathways, leading to sustained airway inflammation. In turn, chronic inflammation can increase the production of reactive oxygen species (ROS), thereby exacerbating oxidative stress. This vicious cycle contributes to airway remodeling, reduced lung function, and disease progression. This review emphasizes the central roles of inflammation and oxidative stress in two of the most prevalent hypoxemic conditions, chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA), as well as their involvement in the development of major comorbidities. A comprehensive understanding of these processes is crucial to developing therapeutic strategies aimed at reducing oxidative stress and inflammation for the effective management and treatment of CRDs and their comorbidities. It also underscores the crucial role of hypoxia and its transcriptional effects, mediated by hypoxia-inducible factors (HIF), as a primary driver of disease progression through the promotion of oxidative stress and inflammation. Another key element is the rapid advancement of Artificial Intelligence (AI), which presents promising strategies to mitigate the global burden of CRDs. AI holds potential for reducing healthcare costs while improving diagnostic specificity, enabling earlier detection, and optimizing disease monitoring and management. This review explores the current landscape and future prospects of AI in transforming the diagnosis, clinical management, and prognosis of these respira-tory disorders.
- 15 May 2025
- Published by MDPI AG in Preprints.org
Open AccessOxidative Stress and Inflammation in COPD and Sleep Apnea and Its Comorbidities. Molecular Insights and Artificial Intelligence Approaches in Diagnosis and Prognosis
In chronic respiratory diseases (CRDs), oxidative stress and inflammation exhibit a strong pathophysiological interplay, playing essential roles in the onset and progression of these conditions and their associated comorbidities. Oxidative stress can activate inflammatory pathways, leading to sustained airway inflammation. In turn, chronic inflammation can increase the production of reactive oxygen species (ROS), thereby exacerbating oxidative stress. This vicious cycle contributes to airway remodeling, reduced lung function, and disease progression. This review emphasizes the central roles of inflammation and oxidative stress in two of the most prevalent hypoxemic conditions, chronic obstructive pulmonary disease (COPD) and obstructive sleep apnea (OSA), as well as their involvement in the development of major comorbidities. A comprehensive understanding of these processes is crucial to developing therapeutic strategies aimed at reducing oxidative stress and inflammation for the effective management and treatment of CRDs and their comorbidities. It also underscores the crucial role of hypoxia and its transcriptional effects, mediated by hypoxia-inducible factors (HIF), as a primary driver of disease progression through the promotion of oxidative stress and inflammation. Another key element is the rapid advancement of Artificial Intelligence (AI), which presents promising strategies to mitigate the global burden of CRDs. AI holds potential for reducing healthcare costs while improving diagnostic specificity, enabling earlier detection, and optimizing disease monitoring and management. This review explores the current landscape and future prospects of AI in transforming the diagnosis, clinical management, and prognosis of these respira-tory disorders.